Specialized Care for Therapy-Resistant Cancer Patients in United Arab Emirates
Managing metastatic and therapy-resistant cancers is highly challenging because current treatments often fail to address the root causes of cancer. Tumor diversity, resistance to therapies, the supportive tumor microenvironment, limitations of conventional treatments, complexity of metastasis, and personalization hurdles all contribute to these challenges. While new approaches like combination therapies and precision medicine show promise, there's a pressing need for innovative solutions targeting the core mechanisms behind cancer progression.
Our team in Germany won a deep insight into this process in the last 20 years and published several original papers in this respect demonstrating the essential roles played by the low oxygen perfusion in so called hypoxic areas forcing primary tumor cells to shift their energetic metabolism from a mitochondrial oxidative phosphorilation to a cytosolic aerobic glycolysis (Warburg effect) generating and transfering large amounts of protons (H+) and lactic acid outside of the tumor cells. The resulting peripheral acidosis efficiently blocks the immune cells of the host (monocyte and macrophages) to access the appropriate receptors on the tumor cell membranes and induce their lysis or apoptosis.
Tumor transcription factors like HIF-1 and MYC as well as tumor specific Carboanhydrases are strongly supporting both the aerobic glycolysis and the transfer of acidic equivalents outside of the cells, thus maintaining an intracellular alcalosis state, mandatory for continuous cellular replications.
Accumulation of large deposits of heavy metals (like Hg, Sn, Ni, Co, Cr, As, Pb, Zn Fe,) pesticides, PCBs, DDT, HCB, phtalates, etc. in the tumor mass, generating a high oxidative stress via free radicals, is in turn responsible for the continuous genetic mutations in all tumor centers. It's easy to understand that as long as every tumor nodule has his own DNA mutations, his own form of glucose, glutamine or fatty acid metabolism and his own resistance pattern against radiation or chemotherapy, it is practicaly impossible to destroy all tumor nodules with a first line therapy protocol, even in the same tumor (see references).
Clinical Scan Results
PET-CT documented outcomes from patients treated with the German Integrative Cancer Therapy Concept.
Why Conventional Cancer Treatment Falls Short
Six fundamental challenges mean that standard radiation and chemotherapy cannot achieve durable remission in metastatic and therapy-resistant cases.
Tumour Diversity
Every tumour nodule carries its own DNA mutations, its own metabolic profile, and its own resistance pattern — making a single first-line protocol insufficient.
Therapy Resistance
Cancer cells rapidly develop resistance to radiation and chemotherapy, limiting the long-term effectiveness of standard treatments.
Tumour Microenvironment
A supportive acidic microenvironment actively shields tumour cells from immune detection and conventional drug penetration.
Metastasis Complexity
Metastatic spread involves multiple organ systems with distinct biological characteristics that require highly personalised interventions.
Epigenetic Drivers Ignored
Heavy metals, pesticides and environmental toxins accumulate in tumour tissue — driving continuous genetic mutations that standard therapies do not address.
Immune Suppression
Peripheral acidosis from the Warburg effect blocks host immune cells (monocytes and macrophages) from accessing tumour cell membranes to induce lysis or apoptosis.
The Science Behind Cancer Progression
The Warburg Effect
Low oxygen perfusion in hypoxic tumour areas forces cancer cells to shift their energy metabolism from mitochondrial oxidative phosphorylation to cytosolic aerobic glycolysis — generating large amounts of protons (H⁺) and lactic acid that are expelled outside the tumour cells.
Peripheral Acidosis & Immune Escape
The resulting acidic microenvironment efficiently blocks the host's immune cells (monocytes and macrophages) from accessing the appropriate receptors on tumour cell membranes — preventing lysis or apoptosis of cancer cells.
HIF-1, MYC & Carboanhydrases
Tumour transcription factors HIF-1 and MYC, alongside tumour-specific Carboanhydrases, strongly support aerobic glycolysis and maintain an intracellular alkalosis state — mandatory for continuous cellular replication.
Heavy Metals & Continuous Mutations
Accumulation of heavy metals (Hg, Sn, Ni, Co, Cr, As, Pb, Zn, Fe), pesticides, PCBs and phthalates in tumour tissue generates high oxidative stress — driving continuous genetic mutations across all tumour nodules, each with its own resistance pattern.
Evidence-Based Integrative Therapy
Our 7-component protocol targets the universal hallmarks of cancer cells in both primary tumours and metastases — combining innovative metabolic interventions with personalised immunotherapy to enhance efficacy while minimising side effects.
Aerobic Glycolysis & Glutaminolysis Inhibitors
Cancer cells are uniquely dependent on aerobic glycolysis (the Warburg effect) and glutaminolysis for energy and biosynthetic precursors. We target these pathways using genistein (a soy isoflavone that inhibits glucose transporter expression), oxythiamine (a thiamine antagonist blocking the pentose phosphate pathway), dichloroacetate (DCA, which reactivates pyruvate dehydrogenase and forces mitochondrial oxidative metabolism), and ketone body derivatives that starve tumour cells of their preferred fuel. All agents have demonstrated safety in both animal models and human clinical studies, with no meaningful toxicity at therapeutic doses.
Extracellular Acidosis Inhibitors
Tumour-derived lactic acid and CO₂ create a profoundly acidic extracellular environment that physically prevents host immune cells — particularly monocytes and macrophages — from accessing and destroying tumour cells. The enzyme family responsible for maintaining this acidic shield is the carboanhydrases (CA IX, CA XII), which are overexpressed in hypoxic tumour zones. We inhibit these enzymes using acetazolamide, sulphonamide derivatives, and natural coumarins — neutralising extracellular acidosis, restoring immune cell access to tumour membranes, and reopening the pathway to immune-mediated tumour cell lysis and apoptosis. All agents are free of clinically significant side effects at the doses employed.
High-Dose Intravenous Vitamin C
At pharmacological concentrations achievable only through intravenous administration, vitamin C acts as a pro-oxidant rather than an antioxidant. In the presence of the elevated transition metal concentrations (iron, copper, nickel, cobalt) documented within tumour tissue, ascorbate undergoes redox cycling — generating superoxide radicals and hydrogen peroxide directly at the tumour site. These reactive oxygen species overwhelm the antioxidant defences of cancer cells, inducing both apoptosis and necrosis of tumour cells selectively. Normal cells, with intact catalase activity, are protected. This mechanism has been documented in multiple peer-reviewed publications from our research group and is administered under full medical supervision with pre- and post-infusion monitoring.
Natural Polyphenols
Several plant-derived polyphenols demonstrate highly selective pro-oxidative activity within the heavy-metal-rich tumour microenvironment. Curcumin (from turmeric), artemisinin (from Artemisia annua), epigallocatechin gallate (EGCG from green tea), and a range of substituted phenols generate superoxide radicals and semiquinone intermediates specifically in the presence of elevated iron, nickel, and cobalt concentrations found in tumour tissue — concentrations that are dramatically higher than in surrounding healthy tissue. This selectivity is critical: the same compounds that are cytotoxic to cancer cells are inert or mildly antioxidant in normal tissue. Doses, combinations, and cycling schedules are individualised based on tumour type and heavy metal burden.
Pro-Oxidative Interventions
Cancer cells maintain a delicately balanced intracellular redox state that is essential for continuous replication. When this redox equilibrium is disrupted, cancer cells — unlike normal cells — lack the reserve capacity to compensate, and undergo apoptosis. We exploit this metabolic vulnerability through a structured combination of: whole-body hyperthermia (raising core temperature to levels that selectively stress cancer cell membranes), short-term therapeutic fasting (3–5 days, which depletes tumour glucose while inducing protective autophagy in normal cells), ketogenic dietary phases (further reducing glycolytic substrate availability), and structured physical exercise protocols (which shift systemic metabolism away from anaerobic glycolysis). Each intervention is sequenced and monitored as a clinical protocol, not as a lifestyle recommendation.
Personalised Immunotherapy
Checkpoint inhibitor immunotherapy — using agents such as nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), and atezolizumab (anti-PD-L1) — has transformed oncology. However, response rates vary enormously depending on the immune profile of the individual tumour. At GIMC, checkpoint inhibitor selection is not based on tumour type alone but on therapy resistance testing performed directly on circulating tumour cells (CTCs) isolated from the patient's blood. This allows us to identify which specific checkpoint pathways are active in each patient's cancer, and to select the agent or combination most likely to restore effective tumour immune surveillance. This personalised immunotherapy layer is integrated with the metabolic and pro-oxidative components of the protocol to achieve synergistic effects.
Anti-Cancer Nutrition Protocol
Nutrition is not adjunctive in this protocol — it is mechanistically integral. The anti-cancer nutrition plan is designed to remove substrates that cancer cells depend on and to provide compounds that reinforce the therapeutic effects of all other protocol components. The diet is low in: simple sugars and refined flour (glycolytic substrate), glutamine-rich foods (glutaminolysis substrate), iron and nickel (transition metals that accelerate tumour oxidative stress in uncontrolled ways), folic acid (which accelerates DNA replication in rapidly dividing cells), fat peroxides (pre-formed lipid radicals), and alcohol. It is rich in: omega-3 fatty acids (anti-inflammatory, membrane-stabilising), vitamin D (immune modulation, apoptosis induction), carotenoids, plant proteins, sphingolipids, phytosterols, isoflavonoids and polyphenols (selective pro-oxidative and anti-proliferative), L+ lactic acid (microbiome support), and pro-oxidative vegetable juices freshly prepared from specified botanical sources.
For a deeper insight into our cancer therapy concept, please refer to our peer-reviewed original paper "Metabolic hallmarks of cancer cells as targets for integrative therapies" — published in the Journal of Translational Science, 2020.
Collaboration & Implementation
Our oncology department at GIMC Dubai is dedicated to patients facing therapy-resistant cancer. We specialise in treating those who have not responded to standard radiation or chemotherapy — with innovative protocols designed to align with and complement guideline therapies practised across UAE oncology hospitals.
Collaboration is at the heart of our mission. We actively build partnerships with other cancer treatment centres in the UAE — sharing expertise, improving treatment strategies, and achieving better outcomes for patients with complex and challenging cases.
At-Home Care Support
We equip patients and families with the knowledge and resources to manage care effectively after discharge.
UAE Partnership Network
Active collaboration with cancer centres across the UAE — open communication and joint clinical efforts.
Compassionate Oncology
We aspire to offer hope to patients and families through advanced options and comprehensive support.
Scientific References
Seek Advanced Integrative Cancer Care
If you or a loved one has not responded to standard cancer therapies, our specialists are ready to develop a personalised integrative treatment protocol — evidence-based and compassionately delivered.